AtriCure, Inc.ATRCEarnings & Financial Report
AtriCure, Inc. is a global medical device company specializing in the research, development, and manufacturing of innovative surgical tools and therapeutic solutions for treating atrial fibrillation and associated cardiac conditions. Its core customers include hospitals, cardiac surgery centers, and healthcare providers across North America, Europe, and the Asia Pacific region, with products designed to support safer, more effective minimally invasive cardiac procedures.
Revenue
$134.3M
Gross Profit
$101.3M
Operating Profit
$208.0K
Net Profit
$-267.0K
Gross Margin
75.5%
Operating Margin
0.2%
Net Margin
-0.2%
YoY Growth
15.8%
EPS
$-0.01
AtriCure, Inc. Q3 FY2025 Financial Summary
AtriCure, Inc. reported revenue of $134.3M (up 15.8% YoY) for Q3 FY2025, with a net profit of $-267.0K (up 96.6% YoY) (-0.2% margin). Cost of goods sold was $32.9M, operating expenses totaled $101.1M.
Key Financial Metrics
| Total Revenue | $134.3M |
|---|---|
| Net Profit | $-267.0K |
| Gross Margin | 75.5% |
| Operating Margin | 0.2% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
AtriCure, Inc. Q3 FY2025 revenue of $134.3M breaks down across 5 segments, led by Appendage Management at $45.5M (33.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Appendage Management | $45.5M | 33.8% |
| Openheart | $35.6M | 26.5% |
| Other | $25.0M | 18.6% |
| Pain Management | $20.8M | 15.5% |
| Minimally Invasive | $7.4M | 5.5% |
AtriCure, Inc. Revenue by Segment — Quarterly Trend
AtriCure, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Appendage Management and Openheart) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Appendage Management | — | $45.5M | $45.5M | $45.1M |
| Openheart | — | $38.5M | $35.6M | $36.5M |
| Other | $25.0M | $26.2M | $25.0M | $25.6M |
| Pain Management | — | $22.6M | $20.8M | $21.2M |
| Minimally Invasive | — | $7.7M | $7.4M | $7.8M |
AtriCure, Inc. Annual Revenue by Year
AtriCure, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $534.5M).
| Year | Annual Revenue |
|---|---|
| 2025 | $534.5M |
| 2024 | $465.3M |
| 2023 | $399.2M |
| 2022 | $330.4M |
AtriCure, Inc. Quarterly Revenue & Net Profit History
AtriCure, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $141.2M | +14.3% | $108.0K | 0.1% |
| Q4 FY2025 | $140.5M | +13.1% | N/A | N/A |
| Q3 FY2025 | $134.3M | +15.8% | $-267.0K | -0.2% |
| Q2 FY2025 | $136.1M | +17.1% | $-6.2M | -4.5% |
| Q1 FY2025 | $123.6M | +13.6% | $-6.7M | -5.5% |
| Q4 FY2024 | $124.3M | +16.6% | N/A | N/A |
| Q3 FY2024 | $115.9M | +17.9% | $-7.9M | -6.8% |
| Q2 FY2024 | $116.3M | +15.2% | $-8.0M | -6.9% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $116.3M | $115.9M | $124.3M | $123.6M | $136.1M | $134.3M | $140.5M | $141.2M |
| YoY Growth | 15.2% | 17.9% | 16.6% | 13.6% | 17.1% | 15.8% | 13.1% | 14.3% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $597.3M | $615.1M | $609.3M | $591.6M | $608.8M | $635.4M | $654.2M | $644.0M |
| Liabilities | $135.2M | $150.0M | $148.4M | $137.0M | $144.4M | $158.9M | $162.2M | $152.3M |
| Equity | $462.1M | $465.0M | $461.0M | $454.6M | $464.5M | $476.5M | $491.9M | $491.7M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $7.4M | $20.0M | $5.8M | $-11.0M | $21.6M | $26.7M | $20.0M |